Flyer Biosimilars

2 Biosimilars Introduction to the subject Market for biosimilars Role of the health insurance funds Role of the Associations of Statutory Health Insurance Physicians Substitutability biosimilars / bioidenticals Role of the KVs and other stakeholders Development of a tender strategy Development of a tender strategy for SHI Development of infliximab and its biosimilars from 2014 to 2017 Development of a tender strategy for PHI The product availability